Regeneron

Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Mon, 03/28/22 - 10:20 am
Eli Lilly
lebrikizumab
Demira
Sanofi
Regeneron
Dupixent
atopic dermatitis
BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC
Endpoints
Tue, 03/8/22 - 10:41 am
BioNTech
Regeneron
lung cancer
vaccines
MRNA
Libtayo
Regeneron loses bid to scrap infringement lawsuit linked to COVID antibody cocktail
Fierce Pharma
Fri, 03/4/22 - 10:20 am
Regeneron
Pfizer
BioNTech
patents
COVID-19
legal
antibody cocktail
Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win
Fierce Pharma
Mon, 02/28/22 - 11:42 pm
Sanofi
Regeneron
eosinophilic esophagitis
Dupixent
clinical trials
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies
Fierce Biotech
Wed, 02/23/22 - 09:28 pm
Kodiak Sciences
KSI-301
Eylea
Bayer
Regeneron
Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
Endpoints
Wed, 02/23/22 - 10:31 am
Kiniksa Pharmaceuticals
Regeneron
Arcalyst
Huadong Medicine
Asia
mavrilimumab
Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Pharmaforum
Fri, 02/18/22 - 10:40 am
Sanofi
Regeneron
clinical trials
Dupixent
chronic spontaneous urticaria
COVID-19 treatments earned 4 drugmakers $14B in 2021
Beckers Hospital Review
Tue, 02/8/22 - 11:50 pm
Eli Lilly
Gilead Sciences
Merck
Regeneron
COVID-19
earnings
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Pharmaforum
Mon, 01/31/22 - 10:51 am
Roche
faricimab
Eylea
Bayer
Regeneron
FDA
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Sun, 01/30/22 - 11:53 am
Roche
FDA
bispecific antibodies
Regeneron
Vabysmo
wet age-related macular degeneration
diabetic macular edema
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sun, 01/30/22 - 11:42 am
Sanofi
Regeneron
Libtayo
cervical cancer
post-marketing studies
FDA bans use of Lilly, Regeneron COVID drugs due to Omicron
Pharmaforum
Tue, 01/25/22 - 10:44 am
COVID-19
Eli Lilly
Regeneron
antibodies
Omicron COVID-19 variant
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Thu, 01/20/22 - 11:00 am
Regeneron
FDA
Libtayo
non-small cell lung cancer
Pfizer's Cibinqo snags FDA approval to challenge Sanofi and Regeneron's Dupixent in eczema
Fierce Pharma
Sun, 01/16/22 - 03:53 am
Pfizer
Sanofi
Regeneron
FDA
Cibinqo
atopic dermatitis
JPM 2022: Novartis rewrites the drug launch playbook with Leqvio, and it doesn't plan to stop there, exec says
Fierce Pharma
Thu, 01/13/22 - 11:06 am
JPMHC 2022
Novartis
Leqvio
drug launches
Regeneron
Amgen
Sanofi
Regeneron hands off ex-US rights for cholesterol disorder drug to rare disease specialist Ultragenyx
Endpoints
Fri, 01/7/22 - 10:36 am
Regeneron
evinacumab
Ultragenyx
Leo puts target on Dupixent in US as FDA clears tralokinumab
Pharmaforum
Thu, 12/30/21 - 10:45 am
Sanofi
Regeneron
Dupixent
tralokinumab
FDA
Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug's megablockbuster ambitions
Fierce Pharma
Mon, 12/13/21 - 11:04 am
Sanofi
Regeneron
Dupixent
eczema
pediatric
Take a deep breath: Asthma drug study failed to include Black and Puerto Rican children who could benefit most
Stat
Wed, 12/8/21 - 11:45 pm
Sanofi
Regeneron
asthma
pediatric
COVID-19
clinical trial diversity
November sees Sanofi-Regeneron dethroned after 6-month rule over top TV ad spender list
Fierce Pharma
Sun, 12/5/21 - 10:45 pm
Sanofi
Regeneron
Dupixent
DTC advertising
television ads

Pages